Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer

Hue, Trisha F.; Cummings, Steven R.; Cauley, Jane A.; Bauer, Douglas C.; Ensrud, Kristine E.; Barrett‐Connor, Elizabeth; Black, Dennis M.

doi:10.1001/jamainternmed.2014.3634

Cited by 51 publications

(26 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In order to further address the possibility of confounding, Hue et al [28] examined the results of two randomized clinical trials designed to assess the efficacy of BP for the prevention of osteoporotic fractures (the Fracture Intervention Trial FIT [29] and the Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis HORIZON pivotal trial [30]. Data were collected at clinical centers in the United States (FIT and HORIZON-PFT), in Asia and the Pacific, Europe, North America and South America (HORIZON-PFT).…”

Section: Discussionmentioning

confidence: 99%

The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women

Rouach

Goldshtein

Buch

et al. 2019

Journal of Bone Oncology

View full text Add to dashboard Cite

Background Several observational studies have suggested a protective effect of oral bisphosphonates (BP) on the risk of breast cancer, but no such association has been seen in randomized control trials. The role of oral BP in breast cancer prevention remains unclear. Aim To investigate the association between different levels of BP exposure and breast cancer incidence in a cohort of osteoporotic post-menopausal women. Subjects and methods This historical prospective study was conducted using the computerized databases of Maccabi Healthcare Services (MHS) in Israel. Included in the study were osteopenic and osteoporotic women aged 55–75 years who started BP therapy between 1998 and 2012. The subjects were enrolled in MHS for at least 3 years before therapy initiation, and had a minimum follow-up of 5 years in MHS. Women with a previous cancer, and women treated with selective estrogen receptor modulators (SERMs) were excluded. BP exposure was expressed in quintiles of proportion of days covered (PDC) with BP during follow-up period and cancer incidence was ascertained by the Israel National Tumor Registry. Person-years of follow-up began on January 1st, 1998 and ended at the date of cancer diagnosis, death, or December 31st, 2012, whichever occurred first. Results A total of 11,717 patients (mean age = 66.87 ± 4.38) were eligible for the analysis. During a total of 130,252 person-years of follow-up, (mean 7.2 years) 173 incident cases of breast cancer were diagnosed. Compared to women with a PDC with BP of 20% or lower, the adjusted hazard ratio for breast cancer were HR = 0.81 (95%CI: 0.48–1.39), HR = 0.82 (95%CI: 0.50–1.33), HR = 0.72 (95%CI:0.45–1.15) and HR = 1.14 (95%CI:0.76–1.70) among women with 20–40%, 40–60%, 60%–80%, and 80% or higher, PDC, respectively. Conclusion In this study, we did not find a significant association between oral BP therapy for osteoporosis and the risk of breast cancer in postmenopausal women. The discrepancy between our results and the reports of such an association in observational studies might originate from an indication bias.

show abstract

Section: Discussionmentioning

confidence: 99%

The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women

Rouach

Goldshtein

Buch

et al. 2019

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

“…Therefore, denosumab might have a tremendous clinical impact. In addition, there is ongoing research on the potential anti-cancer mechanisms of bisphosphonates as some ( 160 ) but not all ( 161 ) clinical trials on breast cancer have reported evidence for anti-tumor effects. This anti-neoplastic effects are plausible, considering that bisphosphonates may alter cellular signaling and responsiveness by modification in the isopentenyl diphosphate metabolism, untimely leading to cell death ( 162 , 163 ).…”

Section: Genomic Medicine In Osteoporosis Practicementioning

confidence: 99%

Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders

Trajanoska

Rivadeneira

2020

Front. Endocrinol.

View full text Add to dashboard Cite

Current genetic studies of monogenic and complex bone diseases have broadened our understanding of disease pathophysiology, highlighting the need for medical interventions and treatments tailored to the characteristics of patients. As genomic research progresses, novel insights into the molecular mechanisms are starting to provide support to clinical decision-making; now offering ample opportunities for disease screening, diagnosis, prognosis and treatment. Drug targets holding mechanisms with genetic support are more likely to be successful. Therefore, implementing genetic information to the drug development process and a molecular redefinition of skeletal disease can help overcoming current shortcomings in pharmaceutical research, including failed attempts and appalling costs. This review summarizes the achievements of genetic studies in the bone field and their application to clinical care, illustrating the imminent advent of the genomic medicine era.

show abstract

“…Prostate cancer cells also displayed a synergistic effect when treated with alendronate and simvastatin, thus inhibiting the mevalonate pathway at two different steps and significantly affecting survival and apoptotic pathways ( Rogers et al, 2015 ). Despite these anti-cancer properties, BP use does not reduce the risk of developing breast cancer in post-menopausal women, suggesting their anti-cancer properties still do not reduce initial development of non-skeletal cancer ( Hue et al, 2014 ). The known clinical applications and anti-neoplastic properties of BP are reviewed in Van Acker et al (2016) , while many clinical trials for the use of BP in cancer patients are still ongoing.…”

Section: Introductionmentioning

confidence: 99%

Bisphosphonate conjugation for bone specific drug targeting

et al. 2018

View full text Add to dashboard Cite

Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bone remains an important goal for achieving effective treatments. Drug targeting strategies have improved drug localization to bone by taking advantage of the high mineral concentration unique to the bone hydroxyapatite matrix, as well as tissue-specific cell types. The bisphosphonate molecule class binds specifically to hydroxyapatite and inhibits osteoclast resorption of bone, providing direct treatment for degenerative bone disorders, and as emerging evidence suggests, cancer. These bone-binding molecules also provide the opportunity to deliver other drugs specifically to bone by bisphosphonate conjugation. Bisphosphonate bone-targeted therapies have been successful in treatment of osteoporosis, primary and metastatic neoplasms of the bone, and other bone disorders, as well as refining bone imaging. In this review, we focus upon the use of bisphosphonate conjugates with antineoplastic agents, and overview bisphosphonate based imaging agents, nanoparticles, and other drugs. We also discuss linker design potential and the current state of bisphosphonate conjugate research progress. Ongoing investigations continue to expand the possibilities for bone-targeted therapeutics and for extending their reach into clinical practice.

show abstract

Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer

Cited by 51 publications

References 52 publications

The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women

The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women

Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders

Bisphosphonate conjugation for bone specific drug targeting

Contact Info

Product

Resources

About